It has shown cardiovascular benefits in patients with coronary artery disease in the Cholesterol and Recurrent Events (CARE) and Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial, high-risk primary prevention West of Scotland Coronary Prevention Study (WOSCOPS), and Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) trial.[36,48–50] Simvastatin has a short half-life and is metabolized by CYP3A4 and can be administered without food. This evidence concerns the gene CYP3A4 and coronary artery disorder.